Trial Profile

A Phase 1a/1b Safety and Tolerability Study of FPT155 in Patients with Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FPT 155 (Primary) ; Pembrolizumab (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Five Prime Therapeutics

Most Recent Events

23 Jan 2025 The protocol has been amended to addition in new adverse reaction evaluation endpoints.
23 Jan 2025 Status changed from completed to discontinued.
06 Jan 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com